There is a large, randomized, placebo-controlled answer for chronic kidney disease. The FLOW trial followed participants with type 2 diabetes and CKD for a median of 3.4 years on weekly semaglutide, and a 2026 analysis reports the kidney and survival benefit held across every stratum of severity, down to advanced disease [1]. Baseline kidney function averaged an eGFR of 47, so these were not mild cases, and the wider picture sits in the pooled kidney outcomes.
None of that transfers to someone who has already had a transplant. It is a different population on different medication — immunosuppression that FLOW participants were not taking — and the question after a transplant is not only whether the drug works but whether the graft tolerates it.
The evidence for that question is one retrospective study of 39 patients at a single hospital [2]. Over 13 to 18 months their HbA1c fell from 8.4% to 7.4% and their weight from 99.5 kg to 90.7 kg, both statistically significant, with no significant change in markers of graft function. That is a reassuring direction. It is also 39 people, at one center, looked at after the fact.
The gap matters at a checkout. This desk ranks sellers on published price, and price is the only thing most of them publish — which is the same absence counted in what a good disclosure looks like. A buyer who has had a transplant is making a decision the literature has barely studied, through a form that will not ask about it.
That is not an argument against the drug, and it is not a claim that it is unsafe after a transplant. It is an argument for a nephrologist rather than an intake form. The honest summary is that the benefit is well established in kidney disease, barely studied after transplantation, and that those two sentences describe different people.
If cost is what brought you here, the ordinary questions still apply — whether a rate survives a dose increase, which flat or rising answers for each seller, and what a term commitment actually costs, which term and prepay check works out. They are just not the first question in this case.